Table of Contents Author Guidelines Submit a Manuscript
Psychiatry Journal
Volume 2018, Article ID 9850594, 10 pages
https://doi.org/10.1155/2018/9850594
Research Article

Patterns of Prescription of Psychotropic Medications and Their Adherence among Patients with Schizophrenia in Two Psychiatric Hospitals in Accra, Ghana: A Cross-Sectional Survey

1Department of Pharmacy Practice and Clinical Pharmacy, School of Pharmacy, University of Ghana, Legon, Ghana
2Regional Institute for Population Studies, University of Ghana, Legon, Ghana

Correspondence should be addressed to Irene A. Kretchy; hg.ude.gu@yhcterki

Received 5 July 2017; Revised 17 October 2017; Accepted 21 November 2017; Published 1 January 2018

Academic Editor: Veit Roessner

Copyright © 2018 Sharon Ashong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Dovi, “The silent crisis: Mental health in Africa,” Consultancy Africa Intelligence's Public Health Unit Discussion Paper, vol. 1, 2013. View at Google Scholar
  2. V. C. Doku, A. Wusu-Takyi, and J. Awakame, “Implementing the Mental Health Act in Ghana: any challenges ahead?” Ghana Medical Journal, vol. 46, no. 4, pp. 241–250, 2012. View at Google Scholar · View at Scopus
  3. World Health Organization, The country summary series, Geneva: Mental Health Improvments for Nations Development (MIND), Ghana, October 2007.
  4. E. B. Forster, “A historical survey of psychiatric practice in Ghana,” Ghana Medical Journal, vol. 46, no. 3, pp. 158–162, 2012. View at Google Scholar · View at Scopus
  5. U. M. Read, V. Doku, A. de-Graft, and Aikins., “Schizophrenia and Psychosis in West Africa from the colonial era to the present,” in The Culture of Mental Illness and Psychiatric Practice in Africa, E. Akyeampong, A. Hill, and A. Kleinman, Eds., pp. 73–111, Indiana University Press, Bloomington, Indiana, IN, USA, 2015. View at Google Scholar
  6. L. Sikich, J. A. Frazier, J. McClellan et al., “Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study,” The American Journal of Psychiatry, vol. 165, no. 11, pp. 1420–1431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. K. R. Patel, J. Cherian, K. Gohil, and D. Atkinson, “Schizophrenia: Overview and treatment options,” Pharmacy and Therapeutics, vol. 39, no. 9, pp. 638–645, 2014. View at Google Scholar · View at Scopus
  8. W. W. Eaton, C.-Y. Chen, and E. J. Bromet, “Epidemiology of Schizophrenia,” Textbook in Psychiatric Epidemiology: Third Edition, pp. 263–287, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Bruijnzeel, U. Suryadevara, and R. Tandon, “Antipsychotic treatment of schizophrenia: an update,” Asian Journal of Psychiatry, vol. 11, pp. 3–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Lage and M. K. Hassan, “The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study,” Annals of General Psychiatry, vol. 8, article 7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Osterberg and T. Blaschke, “Adherence to medication,” The New England Journal of Medicine, vol. 353, no. 5, pp. 487–497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. P. Gilmer, V. D. Ojeda, C. Barrio et al., “Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency,” Psychiatric Services, vol. 60, no. 2, pp. 175–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Ascher-Svanum, B. Zhu, D. Faries, N. Furiak, and W. Montgomery, “Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia,” BMC Research Notes, vol. 2, article no. 6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. H. Kennedy, “A review of antidepressant treatments today,” European Neuropsychopharmacology, vol. 16, no. 5, pp. S619–S623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Serretti, A. Chiesa, R. Calati et al., “Side effects associated with psychotropic medications in patients with bipolar disorder: Evidence from two independent samples,” Journal of Psychopharmacology, vol. 27, no. 7, pp. 616–628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. J. B. Kazadi, M. Y. H. Moosa, and F. Y. Jeenah, “Factors associated with relapse in schizophrenia,” South African Journal of Psychiatry, vol. 14, no. 2, pp. 52–62, 2008. View at Google Scholar · View at Scopus
  17. R. Emsley, B. Chiliza, L. Asmal, and B. H. Harvey, “The nature of relapse in Schizophrenia,” BMC Psychiatry, vol. 13, no. 1, article 50, pp. 1–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Kishimoto, V. Agarwal, T. Kishi, S. Leucht, J. M. Kane, and C. U. Correll, “Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics,” Molecular Psychiatry, vol. 18, no. 1, pp. 53–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Akpalu, C. Lund, V. Doku et al., “Scaling up community-based services and improving quality of care in the state psychiatric hospitals: The way forward for Ghana,” South African Journal of Psychiatry, vol. 13, no. 2, pp. 109–115, 2010. View at Google Scholar · View at Scopus
  20. J. Xiao, W. Mi, L. Li, Y. Shi, and H. Zhang, “High relapse rate and poor medication adherence in the chinese population with schizophrenia: Results from an observational survey in the people’s Republic of China,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 1161–1167, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Higashi, G. Medic, K. J. Littlewood, T. Diez, O. Granström, and M. de Hert, “Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review,” Therapeutic Advances in Psychopharmacology, vol. 3, no. 4, pp. 200–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Haddad, C. Brain, and J. Scott, “Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies,” Patient Related Outcome Measures, vol. 5, p. 43, 2014. View at Publisher · View at Google Scholar
  23. M. Birnbaum and Z. Sharif, “Medication adherence in schizophrenia: Patient perspectives and the clinical utility of paliperidone ER,” Patient Preference and Adherence, vol. 2, pp. 233–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Endale Gurmu, E. Abdela, B. Allele, E. Cheru, and B. Amogne, “Rate of nonadherence to antipsychotic medications and factors leading to nonadherence among psychiatric patients in gondar university hospital, Northwest Ethiopia,” Advances in Psychiatry, vol. 2014, Article ID 475812, pp. 1–5, 2014. View at Publisher · View at Google Scholar
  25. S. Teferra, C. Hanlon, T. Beyero, L. Jacobsson, and T. Shibre, “Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: A qualitative study of patients, caregivers and health workers,” BMC Psychiatry, vol. 13, article no. 168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. U. Werneke, T. Turner, and S. Priebe, “Complementary medicines in psychiatry: review of effectiveness and safety,” The British Journal of Psychiatry, vol. 188, pp. 109–121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. N. A. Qureshi and A. M. Al-Bedah, “Mood disorders and complementary and alternative medicine: a literature review,” Neuropsychiatric Disease and Treatment, vol. 9, pp. 639–658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Grover, T. Davuluri, and S. Chakrabarti, “Religion, spirituality, and schizophrenia: a review,” Indian Journal of Psychological Medicine, vol. 36, no. 2, pp. 119–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Schroeder, D. Naber, and C. G. Huber, “Maladaptive personality traits increase subjectively during the course of schizophrenia spectrum disorders,” The Journal of Nervous and Mental Disease, vol. 202, no. 4, pp. 319–323, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Kasckow KFelmet, C. Appelt, R. Thompson, A. Rotondiand, and G. Haas, “Telepsychiatry in the assessment and treatment of schizophrenia,” Clinical schizophrenia related psychoses, vol. 8, no. 1, pp. 21–27A, 2013. View at Google Scholar
  31. E. L. Noordraven, A. I. Wierdsma, P. Blanken, A. F. T. Bloemendaal, and C. L. Mulder, “Depot-medication compliance for patients with psychotic disorders: The importance of illness insight and treatment motivation,” Neuropsychiatric Disease and Treatment, vol. 12, pp. 269–274, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Yalcin-Siedentopf, F. Wartelsteiner, A. Kaufmann et al., “Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics,” International Journal of Neuropsychopharmacology, vol. 18, no. 5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Kaplan, J. Casoy, and J. Zummo, “Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia,” Patient Preference and Adherence, vol. 7, pp. 1171–1180, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. A. O. Adelufosi, T. O. Adebowale, O. Abayomi, and J. T. Mosanya, “Medication adherence and quality of life among Nigerian outpatients with schizophrenia,” General Hospital Psychiatry, vol. 34, no. 1, pp. 72–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. R. E. Hales, S. C. Yudofsky, and L. W. Roberts, The American Psychiatric Publishing Textbook of Psychiatry, American Psychiatric Publishing, 2010. View at Publisher · View at Google Scholar
  36. G. W. Loh, V. H. Mabasa, and M. H. H. Ensom, “Therapeutic drug monitoring in the neurocritical care unit,” Current Opinion in Critical Care, vol. 16, no. 2, pp. 128–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Conca, E. Schmidt, M. Pastore, C. Hiemke, D. Duffy, and G. Giupponi, “Therapeutic drug monitoring in Italian psychiatry,” Pharmacopsychiatry, vol. 21, no. 6, pp. 259–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. R. Maher, M. Maglione, S. Bagley et al., “Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 306, no. 12, pp. 1359–1369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Oppong, I. A. Kretchy, E. P. Imbeah, and B. A. Afrane, “Managing mental illness in Ghana: The state of commonly prescribed psychotropic medicines,” International Journal of Mental Health Systems, vol. 10, no. 1, article no. 28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental state: a practical method for grading the cognitive state of patients for the clinician,” Journal of Psychiatric Research, vol. 12, no. 3, pp. 189–198, 1975. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Naing, T. Winn, and B. N. Rusli, “Practical Issues in Calculating the Sample Size for Prevalence Studies,” Arch Orofac Sci, vol. 1, pp. 9–14, 2006. View at Google Scholar
  42. L. Waddell and M. Taylor, “A new self-rating scale for detecting atypical or second-generation antipsychotic side effects,” Journal of Psychopharmacology, vol. 22, no. 3, pp. 238–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. D. E. Morisky, L. W. Green, and D. M. Levine, “Concurrent and predictive validity of a self-reported measure of medication adherence,” Medical Care, vol. 24, no. 1, pp. 67–74, 1986. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Ross, A. Walker, and M. J. MacLeod, “Patient compliance in hypertension: Role of illness perceptions and treatment beliefs,” Journal of Human Hypertension, vol. 18, no. 9, pp. 607–613, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Hiemke, P. Baumann, N. Bergemann et al., “AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011,” Pharmacopsychiatry, vol. 44, no. 6, pp. 195–235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Roberts, J. Asare, C. Mogan, E. Adjase, and A. Osei, The mental health system in Ghana-WHO AIMS report, Accra: Kintampo Project/Ghana Ministry of Health, 2013.
  47. V. Patel, “Poverty, inequality and mental health in developing countries,” in Poverty, inequality and health, D. Leon and G. Walt, Eds., Oxford University Press, Oxford, UK, 2001. View at Google Scholar
  48. C. Lloyd, Vocational rehabilitation and mental health, John Wiley and Sons, 2010.
  49. Parliament of the Republic of Ghana, “Act 846 Mental Health Act,” 2012, https://www.google.com/search?tbs=bks:1&q=isbn:0724533613&gws_rd=ssl#q=mental+health+act+846.
  50. P. Sarkar, K. Chakraborty, A. Misra, R. Shukla, and S. P. Swain, “Pattern of psychotropic prescription in a tertiary care center: A critical analysis,” Indian Journal of Pharmacology, vol. 45, no. 3, pp. 270–273, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. D. H. Barlow and V. M. Durand, Abnormal psychology: An integrative approach, Nelson Education, 2011.
  52. L. Culpepper, “A roadmap to key pharmacologic principles in using antipsychotics,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 9, no. 6, pp. 444–454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. K. M. Brophy, H. Scarlett-Ferguson, K. S. Webber, A. C. Abrams, and C. B. Lammon, “Clinical drug therapy for Canadian practice,” Lippincott Williams and Wilkins, pp. 321–326, 2010. View at Google Scholar
  54. S. Raja, S. Kippen, and M. R. Reich, “Access to psychiatric medicines in Africa,” in Culture, Mental Illness and Psychiatric Practice in Africa, E. Akyeampong, A. Hill, and A. Kleinman, Eds., Indiana University Press, Bloomington, IN, USA, 2009. View at Google Scholar
  55. A. Ofori-Atta, U. M. Read, and C. Lund, “A situation analysis of mental health services and legislation in Ghana: Challenges for transformation,” South African Journal of Psychiatry, vol. 13, no. 2, pp. 99–108, 2010. View at Google Scholar · View at Scopus
  56. E. H. Drummond, The Complete Guide to Psychiatric Drugs: Straight Talk for Best Results, John Wiley and Sons, 2006.
  57. J. Mintzer and A. Burns, “Anticholinergic side-effects of drugs in elderly people,” Journal of the Royal Society of Medicine, vol. 93, pp. 457–462, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. H. J. Witchel, J. C. Hancox, and D. J. Nutt, “Psychotropic drugs, cardiac arrhythmia, and sudden death,” Journal of Clinical Psychopharmacology, vol. 23, no. 1, pp. 58–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Narang, M. El-Refai, R. Parlapalli et al., “Antipsychotic drugs: Sudden cardiac death among elderly patients,” Psychiatry, vol. 7, no. 10, pp. 1550–5952, 2010. View at Google Scholar · View at Scopus
  60. D. R. Rosenberg and S. Gershon, Pharmacotherapy for child and adolescent psychiatric disorders, CRC Press, 2002. View at Scopus
  61. J. Kamin, S. Manwani, and D. Hughes, “Extrapyramidal side effects in the psychiatric emergency service,” Psychiatric Services, vol. 51, no. 3, pp. 287–289, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. A. S. Virani, K. Z. Bezchlibnyk-butler, J. J. Jeffries, and R. M. Procyshyn, Clinical handbook of psychotropic drugs, Hogrefe, 2012.
  63. M. De Hert, J. Detraux, R. Van Winkel, W. Yu, and C. U. Correll, “Metabolic and cardiovascular adverse effects associated with antipsychotic drugs,” Nature Reviews Endocrinology, vol. 8, no. 2, pp. 114–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Shaw and D. R. DeMaso, Clinical manual of pediatric psychosomatic medicine: Mental health consultation with physically ill children and adolescents, 2007.
  65. O. Ruetsch, A. Viala, H. Bardou, P. Martin, and M. N. Vacheron, “Psychotropic drugs induced weight gain: A review of the literature concerning epidemiological data, mechanisms and management,” L'Encéphale, vol. 31, no. 4 I, pp. 507–516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. W. White, L. Elmore, D. R. Luthin, and M. E. Cates, “Psychotropic-induced weight gain: a review of management strategies,” Consultant, vol. 53, no. 3, pp. 153–160, 2013. View at Google Scholar · View at Scopus
  67. W. Guo, G.-X. Guo, C. Sun et al., “Therapeutic drug monitoring of psychotropic drugs in china: a nationwide survey,” Therapeutic Drug Monitoring, vol. 35, no. 6, pp. 816–822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Gex-Fabry, A. E. Balant-Gorgia, and L. P. Balant, “Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication,” Therapeutic Drug Monitoring, vol. 25, no. 1, pp. 46–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Schoretsanitis, E. Spina, C. Hiemke, and J. de Leon, “A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone,” Expert Review of Clinical Pharmacology, vol. 10, no. 9, pp. 965–981, 2017. View at Publisher · View at Google Scholar
  70. G. Ramankutty, “Olanzapine-induced destabilization of diabetes in the absence of weight gain,” Acta Psychiatrica Scandinavica, vol. 105, no. 3, pp. 235-236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Lambert, “Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis,” Australian Prescriber, vol. 34, no. 4, pp. 97–99, 2011. View at Publisher · View at Google Scholar · View at Scopus